Dosing and uses of Pataday, Patanol (olopatadine ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.1%
- 0.2%
- 0.7%
Allergic Conjunctivitis
Indicated for the treatment of ocular itching associated with allergic conjunctivitis
0.1% solution (Patanol): 1 gtt BID in affected eye(s) at an interval of 6-8 hr
0.2% solution (Pataday): 1 gtt in affected eye(s) qDay
0.7% (Pazeo): 1 gtt in affected eye(s) qDay
Pediatric dosage forms and strengths
ophthalmic solution
- 0.1%
- 0.2%
- 0.7%
Allergic Conjunctivitis
Indicated for the treatment of ocular itching associated with allergic conjunctivitis
<2 years (Pataday, Pazeo) or <3 years (Patanol): Safety and efficacy not established
0.1% solution (Patanol): 1-2 gtt BID in affected eye(s) at an interval of 6-8 hr
0.2% solution (Pataday): 1 gtt in affected eye(s) qDay
0.7% solution (Pazeo): 1 gtt in affected eye(s) qDay
Pataday, Patanol (olopatadine ophthalmic) adverse (side) effects
1-10%
Headache (7%)
Asthenia (<5%)
Blurred vision (<5%)
Burning or stinging (<5%)
Cold syndrome (<5%)
Dry eye (<5%)
Foreign body sensation (<5%)
Hyperemia (<5%)
Hypersensitivity (<5%)
Keratitis (<5%)
Lid edema (<5%)
Nausea (<5%)
Pharyngitis (<5%)
Pruritus (<5%)
Rhinitis (<5%)
Sinusitis (<5%)
Taste perversion (<5%)
Warnings
Contraindications
Documented hypersensitivity
Cautions
Remove contact lenses prior to administration; wait 10 min after administration before reinsertion
Do not use contact lenses if eyes are red
Pregnancy and lactation
Pregnancy category: C
Lactation: Unknown if distributed into breast milk; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Pataday, Patanol (olopatadine ophthalmic)
Mechanism of action
Antihistamine (H1 antagonist); inhibits release of histamine from mast cells and histamine induced effects on conjunctival epithelial cells.
Pharmacokinetics
Absorption: Limited systemic
Half-Life: 3 hr
Protein binding: ~55%
Metabolites: N-desmethyl olopatadine; olopatadine N-oxide
Half-life: 3 hr
Excretion: Urine (60-70%); feces (17%)
